Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: A retrospective cohort study

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 1, 2003, Pages 171-174

  Bongiovanni, Marco ^a   Bini, Teresa ^a   Tordato, Federica ^a   Cicconi, Paola ^a   Melzi, Sara ^a   Repetto, Dolores ^a   Sollima, Salvatore ^a   Rusconi, Stefano ^a   d'Arminio Monforte, Antonella ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MONITORING; KIDNEY FAILURE; LIPODYSTROPHY; LIVER FAILURE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PARESTHESIA; RASH; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; TREATMENT OUTCOME;

EID: 0037254088     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg045     Document Type: Article

References (6)

1. Hicks, C., Brun, S., King, M., Marsh, T., Deeks, S., Benson, C. et al. (2001). Kaletra (lopinavir/ritonavir) therapy in single protease inhibitor experienced patients: 144 week follow-up. In Eighth European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, Greece, October 2001. Poster 220.
2. Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C. M. et al. (1998). ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy 48, 3218-24.
3. Isacson, J., Kempf, D. J., Calvez, V., Cohen-Codar, I., Descamps, D., Guillevic, E. et al, (2002). Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients. In Ninth Conference on Retrovirus and Opportunistic Infections, Seattle, WA, USA, February 2002. Poster 559-T.
4. Tsuchiya, K., Matsuoka, S., Hachiya, A., Yasuoka, A., Tachikawa, N., Kikuchi, Y. et al. (2001). Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy. AIDS 15 1183-4.
5. Benson, C. A., Deeks, S. G., Brun, S., Gulick, R. M., Eron, J. J., Kessler, H. A. et al. (2002). Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. Journal of Infectious Diseases 185, 599-607.
6. Ruiz, L., Ribera, A., Bonjochi, A., Martinez-Picado, J., Diaz, M., Romen, J. et al. (2002). Virological and immunological benefit of a salvage therapy that includes Kaletra plus Fortovase preceded or not by antiretroviral therapy interruption (TI) in advanced HIV-infected patients (6-month-follow-up). In Ninth Conference on Retrovirus and Opportunistic Infections, Seattle, WA, USA, February 2002. Poster 421-W.